Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Takeshi Mitani
Observed name:
T. Mitani
Institution:
Kurashiki Central Hospital
Observed institution:
Kurashiki Central Hospital
OpenAlex ID:
A5121032885
Second-Line Durvalumab plus Tremelimumab versus Lenvatinib after Atezolizumab plus Bevacizumab Failure in Hepatocellular Carcinoma: A Multi-Center Retrospective Study
2026
·
Masayuki Ueno
, Haruhiko Takeda
, et al.
·
Research Square
PDF
Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study
2026
·
Masayuki Ueno
, Yung-Yeh Su
, et al.
·
Liver Cancer
A simple ABC score for prognosis stratification and treatment selection in advanced hepatocellular carcinoma.
2026
·
Yung-Yeh Su
, Masayuki Ueno
, et al.
·
Journal of Clinical Oncology
PDF
362P Machine learning-based risk prediction of refractoriness to Atezo+Bev therapy in advanced hepatocellular carcinoma
2025
·
T. Mitani
, M. Ueno
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
4
Citation count:
H-index:
I10-index:
Year
Topic
Type
